vs
Amneal Pharmaceuticals, Inc.（AMRX）与Monolithic Power Systems（MPWR）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是Monolithic Power Systems的1.1倍（$814.3M vs $751.2M），Monolithic Power Systems净利率更高（22.9% vs 4.3%，领先18.5%），Monolithic Power Systems同比增速更快（20.8% vs 11.5%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $63.9M），过去两年Monolithic Power Systems的营收复合增速更高（28.1% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Monolithic Power Systems（简称MPS）是一家美国上市企业，总部位于华盛顿州柯克兰市，主营高性能电源管理类产品的研发、生产与销售，目前在全球范围内设有超过15个运营站点，业务覆盖多个国家和地区。
AMRX vs MPWR — 直观对比
营收规模更大
AMRX
是对方的1.1倍
$751.2M
营收增速更快
MPWR
高出9.4%
11.5%
净利率更高
MPWR
高出18.5%
4.3%
自由现金流更多
AMRX
多$44.6M
$63.9M
两年增速更快
MPWR
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $751.2M |
| 净利润 | $35.1M | $171.7M |
| 毛利率 | 36.5% | 55.2% |
| 营业利润率 | 13.8% | 26.6% |
| 净利率 | 4.3% | 22.9% |
| 营收同比 | 11.5% | 20.8% |
| 净利润同比 | 212.9% | -86.3% |
| 每股收益（稀释后） | $0.10 | $3.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXMPWR
| Q4 25 | $814.3M | $751.2M | ||
| Q3 25 | $784.5M | $737.2M | ||
| Q2 25 | $724.5M | $664.6M | ||
| Q1 25 | $695.4M | $637.6M | ||
| Q4 24 | $730.5M | $621.7M | ||
| Q3 24 | $702.5M | $620.1M | ||
| Q2 24 | $701.8M | $507.4M | ||
| Q1 24 | $659.2M | $457.9M |
净利润AMRXMPWR
| Q4 25 | $35.1M | $171.7M | ||
| Q3 25 | $2.4M | $179.8M | ||
| Q2 25 | $22.4M | $135.0M | ||
| Q1 25 | $12.2M | $135.1M | ||
| Q4 24 | $-31.1M | $1.3B | ||
| Q3 24 | $-156.0K | $144.4M | ||
| Q2 24 | $6.0M | $100.4M | ||
| Q1 24 | $-91.6M | $92.5M |
毛利率AMRXMPWR
| Q4 25 | 36.5% | 55.2% | ||
| Q3 25 | 34.9% | 55.1% | ||
| Q2 25 | 39.5% | 55.1% | ||
| Q1 25 | 36.8% | 55.4% | ||
| Q4 24 | 36.0% | 55.4% | ||
| Q3 24 | 38.4% | 55.4% | ||
| Q2 24 | 35.6% | 55.3% | ||
| Q1 24 | 36.1% | 55.1% |
营业利润率AMRXMPWR
| Q4 25 | 13.8% | 26.6% | ||
| Q3 25 | 9.0% | 26.5% | ||
| Q2 25 | 15.4% | 24.8% | ||
| Q1 25 | 14.4% | 26.5% | ||
| Q4 24 | 10.4% | 26.3% | ||
| Q3 24 | 12.6% | 26.5% | ||
| Q2 24 | 13.6% | 23.0% | ||
| Q1 24 | -1.6% | 20.9% |
净利率AMRXMPWR
| Q4 25 | 4.3% | 22.9% | ||
| Q3 25 | 0.3% | 24.4% | ||
| Q2 25 | 3.1% | 20.3% | ||
| Q1 25 | 1.8% | 21.2% | ||
| Q4 24 | -4.3% | 201.8% | ||
| Q3 24 | -0.0% | 23.3% | ||
| Q2 24 | 0.9% | 19.8% | ||
| Q1 24 | -13.9% | 20.2% |
每股收益（稀释后）AMRXMPWR
| Q4 25 | $0.10 | $3.50 | ||
| Q3 25 | $0.01 | $3.74 | ||
| Q2 25 | $0.07 | $2.81 | ||
| Q1 25 | $0.04 | $2.81 | ||
| Q4 24 | $-0.10 | $25.71 | ||
| Q3 24 | $0.00 | $2.95 | ||
| Q2 24 | $0.02 | $2.05 | ||
| Q1 24 | $-0.30 | $1.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $1.3B |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $3.5B |
| 总资产 | $3.7B | $4.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXMPWR
| Q4 25 | $282.0M | $1.3B | ||
| Q3 25 | $201.2M | $1.3B | ||
| Q2 25 | $71.5M | $1.1B | ||
| Q1 25 | $59.2M | $1.0B | ||
| Q4 24 | $110.6M | $862.9M | ||
| Q3 24 | $74.0M | $1.5B | ||
| Q2 24 | $43.8M | $1.3B | ||
| Q1 24 | $46.5M | $1.3B |
总债务AMRXMPWR
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXMPWR
| Q4 25 | $-70.8M | $3.5B | ||
| Q3 25 | $-109.5M | $3.4B | ||
| Q2 25 | $-112.1M | $3.2B | ||
| Q1 25 | $-131.7M | $3.1B | ||
| Q4 24 | $-109.3M | $3.0B | ||
| Q3 24 | $-93.4M | $2.4B | ||
| Q2 24 | $-57.5M | $2.2B | ||
| Q1 24 | $-63.7M | $2.1B |
总资产AMRXMPWR
| Q4 25 | $3.7B | $4.2B | ||
| Q3 25 | $3.6B | $4.1B | ||
| Q2 25 | $3.4B | $3.9B | ||
| Q1 25 | $3.4B | $3.7B | ||
| Q4 24 | $3.5B | $3.5B | ||
| Q3 24 | $3.5B | $2.9B | ||
| Q2 24 | $3.5B | $2.6B | ||
| Q1 24 | $3.5B | $2.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $104.9M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $63.9M |
| 自由现金流率自由现金流/营收 | 13.3% | 8.5% |
| 资本支出强度资本支出/营收 | 2.7% | 5.5% |
| 现金转化率经营现金流/净利润 | 3.72× | 0.61× |
| 过去12个月自由现金流最近4个季度 | $269.9M | $666.2M |
8季度趋势，按日历期对齐
经营现金流AMRXMPWR
| Q4 25 | $130.3M | $104.9M | ||
| Q3 25 | $118.5M | $239.3M | ||
| Q2 25 | $83.8M | $237.6M | ||
| Q1 25 | $7.4M | $256.4M | ||
| Q4 24 | $118.1M | $167.7M | ||
| Q3 24 | $141.8M | $231.7M | ||
| Q2 24 | $39.7M | $141.0M | ||
| Q1 24 | $-4.4M | $248.1M |
自由现金流AMRXMPWR
| Q4 25 | $108.5M | $63.9M | ||
| Q3 25 | $106.2M | $196.8M | ||
| Q2 25 | $61.0M | $189.5M | ||
| Q1 25 | $-5.8M | $216.0M | ||
| Q4 24 | $102.9M | $102.9M | ||
| Q3 24 | $124.8M | $197.9M | ||
| Q2 24 | $29.0M | $109.5M | ||
| Q1 24 | $-13.6M | $232.1M |
自由现金流率AMRXMPWR
| Q4 25 | 13.3% | 8.5% | ||
| Q3 25 | 13.5% | 26.7% | ||
| Q2 25 | 8.4% | 28.5% | ||
| Q1 25 | -0.8% | 33.9% | ||
| Q4 24 | 14.1% | 16.5% | ||
| Q3 24 | 17.8% | 31.9% | ||
| Q2 24 | 4.1% | 21.6% | ||
| Q1 24 | -2.1% | 50.7% |
资本支出强度AMRXMPWR
| Q4 25 | 2.7% | 5.5% | ||
| Q3 25 | 1.6% | 5.8% | ||
| Q2 25 | 3.2% | 7.2% | ||
| Q1 25 | 1.9% | 6.3% | ||
| Q4 24 | 2.1% | 10.4% | ||
| Q3 24 | 2.4% | 5.5% | ||
| Q2 24 | 1.5% | 6.2% | ||
| Q1 24 | 1.4% | 3.5% |
现金转化率AMRXMPWR
| Q4 25 | 3.72× | 0.61× | ||
| Q3 25 | 50.00× | 1.33× | ||
| Q2 25 | 3.74× | 1.76× | ||
| Q1 25 | 0.61× | 1.90× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | 6.62× | 1.40× | ||
| Q1 24 | — | 2.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
MPWR
暂无分部数据
